ACT Biotech Release: Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients
11/14/2011 9:59:34 AM
More...
|
ACT Biotech's Telatinib Demonstrates Significant Progress in Stomach Cancer Treatment; Phase 2 Data to be Presented at American Society of Clinical Oncology
6/2/2011 10:14:49 AM
More...
|
ACT Biotech to Present Significant Progress in Stomach Cancer Treatment at American Society of Clinical Oncology
5/19/2011 10:00:20 AM
More...
|
ACT Biotech Files Special Protocol Assessment With FDA for Phase 3 Trial of Telatinib for Front-Line Treatment of Stomach Cancer
2/28/2011 9:47:26 AM
More...
|
ACT Biotech Release: Phase 2 Data in Stomach Cancer Show Telatinib's Potent Antiangiogenic Activity
1/20/2011 12:35:54 PM
More...
|
ACT Biotech Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer
10/11/2010 11:10:52 AM
More...
|
ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in Gastric Cancer
6/2/2010 10:15:19 AM
More...
|
ACT Biotech Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
1/22/2010 9:39:25 AM
More...
|
ACT Biotech Announces Treatment of First Gastric Cancer Patients with Telatinib in a Phase 2 Clinical Trial in the U.S. and Spain
7/30/2009 8:55:20 AM
More...
|
ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer HealthCare (BAY)
5/7/2008 9:36:37 AM
More...
|